New interview, page-5

So based on this interview, it sounds as though...

#1. Patient 8 has yet to be dosed.
#2. It sounds as though they believe cohort 4 will really be the proving ground.
#3. They really want to push Hep C treatment through to commercialization.
(This I am personally glad to see).

Thanks Nantrix. I found that interview both revealing and reassuring.